PRAC Valproate Review, JCA Scale-Up, Emergency Trial Guidance

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: PRAC's valproate review conclusions, EU JCA scaling to 50 assessments, and EMA's emergency trial guidance. Let's get into it.

SaraPRAC wrapped their June meeting with interesting findings on valproate. They reviewed new data on potential neurodevelopmental disorders in children born to men treated with valproate and concluded the evidence remains inconsistent and the causal role uncertain. They're maintaining existing precautionary measures from 2024.

MarcusThe male patient precautions were already controversial when implemented. This review essentially validates the regulatory limbo we're in - not enough evidence to withdraw them, not enough to strengthen them. From an evidence perspective, this is exactly what you'd expect when the mechanistic pathway isn't clear.

SaraBut that's the problem with precautionary approaches in market access. Once you implement restrictions based on uncertain evidence, you're stuck defending them even when subsequent data doesn't strengthen the case. Male patients are still navigating these precautions, and prescribers are still working around them, regardless of PRAC's uncertainty language.

MarcusFair point, but the alternative was ignoring potential signals entirely. PRAC made the right call maintaining existing measures rather than either escalating or completely reversing course. The evidence threshold for removing safety restrictions is rightfully higher than for implementing them.

SaraThe EU JCA programme is scaling significantly. The Commission published another tovorafenib report on June 9, and ICON's reporting that the 2026 Work Programme anticipates approximately 50 JCAs for medicinal products. Medical device JCAs are launching in June, expanding beyond oncology and ATMPs.

MarcusThat's a massive operational jump from the initial rollout. Fifty JCAs means they're moving from proof-of-concept to industrial scale. The question is whether the assessment quality holds up under that volume pressure. We've seen HTA bodies struggle when they expand scope faster than capacity.

SaraI'm more concerned about the commercial implications. Fifty JCAs means fifty products navigating this process simultaneously, each trying to differentiate their evidence story in a standardized framework. The competitive intelligence burden alone will reshape how companies approach European launches.

MarcusBut that standardization should reduce the total evidence burden across member states. Companies won't need separate dossiers for each national HTA body on scientific assessment.

SaraTheoretically. But we're still waiting to see how divergent the national pricing and reimbursement decisions become when they're all working from the same JCA foundation. Standardized scientific assessment might just push the differentiation pressure downstream to health economic evaluation.

MarcusEMA published draft guidance on conducting clinical trials during public health emergencies. It addresses streamlined authorization processes and collaboration with the PHE Ethics Advisory Group. Consultation runs until April 30, 2026.

SaraThis codifies lessons from recent emergency responses, but I'm skeptical about the practical value. Emergency situations require regulatory flexibility that's hard to capture in static guidance. By the time you're consulting formal procedures, you're not really in emergency mode anymore.

MarcusDisagree completely. The whole point is having frameworks ready before the emergency hits. Ad hoc responses create inconsistency and slow down critical research when time matters most. This guidance establishes clear pathways for streamlined authorization that can be activated immediately.

SaraBut emergencies are inherently unpredictable. The next public health crisis won't look like the last one, and rigid procedures could actually slow responses when the situation doesn't fit the predetermined framework. Regulatory agility matters more than regulatory procedures in genuine emergencies.

MarcusThe guidance specifically addresses collaboration mechanisms with the PHE Ethics Advisory Group. That's institutional learning that prevents repeating coordination failures. You can't rely on regulatory improvisation when lives are at stake.

SaraNovo's oral semaglutide got UK MHRA approval on June 11 for weight management. Adults with BMI 30+ or BMI 27-30 with weight-related comorbidities can now access oral Wegovy. This creates interesting market access dynamics alongside the established injectable formulation.

MarcusThe oral formulation removes the injection barrier, but the real question is whether health systems will differentiate coverage between oral and injectable versions. From a clinical perspective, if the efficacy profiles are comparable, the route of administration shouldn't drive different reimbursement decisions.

SaraThat's naive about patient preferences and adherence realities. Oral formulations typically see better long-term compliance, which should translate to better real-world outcomes and potentially lower total cost of care. Payers should absolutely consider route of administration in coverage decisions.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.